Show simple item record

Stellenwert des Opioidantagonisten Naltrexon bei stationär behandelten Borderline-Patienten

dc.contributor.advisorBandelow, Borwin Prof. Dr.
dc.contributor.authorMeiser, Miriam
dc.date.accessioned2016-09-23T06:51:08Z
dc.date.available2016-10-12T22:50:05Z
dc.date.issued2016-09-23
dc.identifier.urihttp://hdl.handle.net/11858/00-1735-0000-002B-7C0B-D
dc.identifier.urihttp://dx.doi.org/10.53846/goediss-5868
dc.identifier.urihttp://dx.doi.org/10.53846/goediss-5868
dc.language.isodeude
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject.ddc610de
dc.titleStellenwert des Opioidantagonisten Naltrexon bei stationär behandelten Borderline-Patientende
dc.typedoctoralThesisde
dc.title.translatedImprovement of Borderline Personality Disorder with Naltrexone: Results of a retroperspective evaluationde
dc.contributor.refereeBandelow, Borwin Prof. Dr.
dc.date.examination2016-10-05
dc.description.abstractengIntroduction: Although 85% of inpatients with Borderline Personality Disorder (BPD) receive psychotropic drug treatment, no drug is approved for this indication so far. A dysregulation of the endogenous opioid system (EOS) has been posed to underly the neurobiology of BPD. Accordingly, the opioid antagonist naltrexone might be helpful to treat symptoms of BPD. Two small studies showed limited differences of naltrexone vs. placebo on dissociation, which were not significant, perhaps due to the low power of the studies. Methods: A retrospective analysis of the charts of inpatients (n=161) with BPD was performed. Patients were classified as either treatment responders or non-responders. As all patients received multiple psychopharmacological treatments, stepwise logistic regression analysis was performed to detect, which drug contributed most to improvement of symptomatology. Results: None of the drugs applied contributed significantly to improvement, with the exception of naltrexone (odds ratio, p=2,9) Patients treated with naltrexone (n=55, 34,16%) recovered significantly more often and faster and, in particular, showed highly significant reduction of self-harm and suicidal thoughts. Higher doses of naltrexone treatment were more effective than low-dose treatment; however, the latter was still better than any other treatment. Conclusion: Large-scale double-blind studies are warranted to examine the efficacy of opioid antagonists (naltrexone, nalmefene) in BPD.de
dc.contributor.coRefereeFriede, Tim Prof. Dr.
dc.contributor.thirdRefereeBrockmöller, Jürgen Prof. Dr.
dc.subject.gerBorderline Persönlichkeitsstörungde
dc.subject.gerNaltrexonde
dc.subject.gerOpioidantagonistde
dc.subject.gerEOSde
dc.subject.gerPsychopharmakologiede
dc.subject.engBorderline Personality Disorderde
dc.subject.engNaltrexonede
dc.subject.engendogenous opioid systemde
dc.subject.enginpatientsde
dc.subject.engPsychiatryde
dc.identifier.urnurn:nbn:de:gbv:7-11858/00-1735-0000-002B-7C0B-D-0
dc.affiliation.instituteMedizinische Fakultätde
dc.subject.gokfullmedizinde
dc.description.embargoed2016-10-12
dc.identifier.ppn869470183


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record